Home › Follicular Lymphoma
Follicular Lymphoma clinical trials recruiting in the U.S.
108 studies for Follicular Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY24 studies
- Milwaukee, WI19 studies
- Houston, TX18 studies
- Nashville, TN18 studies
- Boston, MA17 studies
- Baldwin Park, CA16 studies
- Seattle, WA16 studies
- Durham, NC15 studies
- Columbus, OH14 studies
- Philadelphia, PA12 studies
- San Antonio, TX12 studies
- Salt Lake City, UT12 studies
- Chicago, IL12 studies
- Dallas, TX11 studies
- Los Angeles, CA11 studies
- Washington, DC11 studies
- Edison, NJ11 studies
- Denver, CO11 studies
- Jacksonville, FL10 studies
- Rochester, MN10 studies
- Atlanta, GA10 studies
- Cincinnati, OH9 studies
- Portland, OR9 studies
- New Haven, CT9 studies
- Cleveland, OH9 studies
- Pittsburgh, PA8 studies
- Miami, FL8 studies
- San Diego, CA8 studies
- Tampa, FL7 studies
- San Francisco, CA7 studies
- Cedar Rapids, IA7 studies
- Charlotte, NC7 studies
- Queens, NY7 studies
- Clifton, NJ7 studies
- Mountain View, CA7 studies
- Austin, TX6 studies
- Winston-Salem, NC6 studies
- Greenburgh, NY6 studies
- St. Louis, MO6 studies
- Lexington, KY5 studies
By state
- Alabama5 studies
- Arizona11 studies
- Arkansas3 studies
- California37 studies
- Colorado14 studies
- Connecticut10 studies
- Delaware4 studies
- District of Columbia4 studies
- Florida25 studies
- Georgia13 studies
- Illinois14 studies
- Indiana7 studies
- Iowa9 studies
- Kansas7 studies
- Kentucky10 studies
- Louisiana8 studies
- Maryland9 studies
- Massachusetts20 studies
- Michigan12 studies
- Minnesota18 studies
- Mississippi3 studies
- Missouri9 studies
- Nebraska4 studies
- New Jersey15 studies
- New Mexico3 studies
- New York30 studies
- North Carolina23 studies
- Ohio24 studies
- Oklahoma4 studies
- Oregon12 studies
- Pennsylvania17 studies
- Rhode Island4 studies
- South Carolina6 studies
- Tennessee19 studies
- Texas35 studies
- Utah12 studies
- Virginia9 studies
- Washington20 studies
- Wisconsin21 studies
Recently updated studies
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06350318A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07634471A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07519772Epco, Zanu, Ritux for R/R FL or MZL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06563596A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03460977Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06784167Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06453044A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05765812A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Sep 21, 2026 · NCT06549595huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07343934NEO100 and High-Grade Meningioma
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT05023018Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06526793Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
RecruitingPhase 3
Ages 12 to 100 · All sexes · Updated Sep 11, 2026 · NCT06784752A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06091254Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07225439A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06043323Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
RecruitingObservational study
Ages 0 and older · All sexes · Updated Sep 2, 2026 · NCT07154823Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 85 · All sexes · Updated Sep 1, 2026 · NCT07546760Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06108232SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.